Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases-Reference-Cited by-同舟云学术

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

Published:2019-07 Issue:8 Volume:17 Page:1533-1540.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Meserve Joseph^ORCID,Aniwan Satimai,Koliani-Pace Jenna L.,Shashi Preeti^ORCID,Weiss Aaron,Faleck David^ORCID,Winters Adam,Chablaney Shreva,Kochhar Gursimran,Boland Brigid S.,Singh Siddharth,Hirten Robert,Shmidt Eugenia,Hartke Justin G.,Chilukuri Prianka^ORCID,Bohm Matthew^ORCID,Sagi Sashidhar Varma,Fischer Monika,Lukin Dana^ORCID,Hudesman David,Chang Shannon^ORCID,Gao Youran,Sultan Keith^ORCID,Swaminath Arun^ORCID,Gupta Nitin^ORCID,Kane Sunanda,Loftus Edward V.,Shen Bo,Sands Bruce E.,Colombel Jean-Frederic,Siegel Corey A.,Sandborn William J.,Dulai Parambir S.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference17 articles.

1. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD;Dulai;Gut,2014

2. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review;Dulai;Clin Gastroenterol Hepatol,2014

3. The safety of vedolizumab for ulcerative colitis and Crohn's disease;Colombel;Gut,2017

4. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium;Dulai;Am J Gastroenterol,2016

5. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies;von Elm;Lancet,2007

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

2. Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab;Intestinal Research;2024-07-31

3. Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers;American Journal of Gastroenterology;2024-07-12

4. Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis;Saudi Journal of Gastroenterology;2024-06-07

5. Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review;Scandinavian Journal of Gastroenterology;2024-04-29